
5mg
❄Liofilizuoti milteliai (neatskiesti)
Nuolaida vienam kiekiui
| Kiekis | Nuolaida | Vieneto kaina |
|---|---|---|
| 5 - 10 | 10% | €53.99 |
| 11 - 20 | 15% | €50.99 |
| 21+ | 20% | €47.99 |
Griežtas trečiųjų šalių bandymas
Kiekviena mūsų tiriamų cheminių medžiagų ir peptidų partija atliekama nepriklausomų trečiosios šalies laboratorinių grynumo ir tapatumo bandymų.
Iš viso: €59.99
Cagrilintide is a long-acting amylin receptor agonist — a next-gen analog of the hormone amylin, which is co-secreted with insulin. It works by slowing gastric emptying, increasing fullness, and regulating hunger signals at the brainstem level. Unlike GLP-1s alone, Cagrilintide attacks obesity from a complementary angle — and when stacked with Semaglutide, results are clinically superior to either compound alone.
Cagrilintide has been evaluated in multiple Phase 2 and Phase 3 clinical trials:
Cagrilintide demonstrates significant and clinically relevant weight loss, especially when combined with GLP-1 receptor agonists, representing a dual-mechanism approach to obesity treatment.
This product is not a drug or food and should be handled by qualified professionals in laboratory conditions. All product information is provided for educational purposes only.